Pembrolizumab in PD-L1-Positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-Related Toxicity Events Patterns: Original Scientific Article. ADMET DMPK 2025, 2956. https://doi.org/10.5599/admet.2956.